Beam Therapeutics is trading 4.56% up now at $27.05 as management maintained its goal of filing the risto-cel BLA as early as year-end 2026.
- Third-quarter loss of $1.28 per share and revenue of $307,000 were both below estimates; revenue fell sharply from $9.7 million a year earlier.
- Available financing could fund operations into mid-2029.
- Shares reversed the prior session’s 4.99% decline while the biotech sector fell 2.39%; no trading-volume details were provided.